BriaCell Completes Bria-PROS+ Manufacturing, Eyes Phase 1/2a Prostate Cancer Trial
BriaCell has completed manufacturing clinical supplies of its next-generation personalized cell-based immunotherapy Bria-PROS+ and plans to initiate a Phase 1/2a prostate cancer trial in coming months. BriaCell received a $2 million grant from the US National Cancer Institute and preclinical data showed activation of T-cells, dendritic cells and NK cells.
1. Manufacturing Completion and Trial Plans
BriaCell has finalized manufacturing clinical supplies of Bria-PROS+, its off-the-shelf cell-based immunotherapy candidate for prostate cancer, and will initiate a Phase 1/2a clinical study in the coming months to assess safety and preliminary efficacy in patients unresponsive to standard treatments.
2. Grant Funding Support
In August 2025, BriaCell secured a $2 million non-dilutive grant from the US National Cancer Institute to underwrite manufacturing and planned clinical evaluation of Bria-PROS+, bolstering resources without diluting shareholder equity.
3. Preclinical Immunogenicity Findings
Preclinical data demonstrated Bria-PROS+ activates adaptive and innate immunity, including naïve T-cell proliferation, dendritic cell maturation and NK cell activation, supporting its potential as a novel immunotherapy for prostate cancer.